Neurophet Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 118

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 30

Neurophet General Information

Description

Developer of a neuroscience simulation software designed to predict and investigate Alzheimer's stimulation effects. The company offers a three-dimensional brain model using magnetic resonance imaging data and a deep learning engine and offers stimulation parameter guidance to concentrate its effect on the target region using numerical optimization techniques, enabling clinicians to predict and visualize the stimulus effect on the brain.

Contact Information

Website
www.neurophet.com
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • Samwon Tower 12th Floor
  • 124 Teheran-ro
  • Seoul, Gangnam-gu 06234
  • South Korea
+82 00-0000-0000
Primary Industry
Decision/Risk Analysis
Vertical(s)
Artificial Intelligence & Machine Learning, TMT, Life Sciences
Corporate Office
  • Samwon Tower 12th Floor
  • 124 Teheran-ro
  • Seoul, Gangnam-gu 06234
  • South Korea
+82 00-0000-0000

Neurophet Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurophet Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. IPO 27-Aug-2024 000.00 Announced Generating Revenue
11. Later Stage VC 29-Feb-2024 00000 000.00 Completed Generating Revenue
10. Later Stage VC (Series C) 06-Nov-2023 000.00 000.00 Completed Startup
9. Accelerator/Incubator 05-Sep-2023 000.00 Completed Startup
8. Later Stage VC (Series B) 09-Nov-2021 000.00 000.00 Completed Startup
7. Later Stage VC (Series A) 30-Jan-2020 00.000 00.000 Completed Startup
6. Early Stage VC 00000 00.000 Completed Startup
5. Grant 01-Nov-2017 00000 00000 Completed Startup
4. Accelerator/Incubator 01-Nov-2016 $617K $776K Completed Startup
3. Accelerator/Incubator 01-Jan-2016 $158K Completed Startup
To view Neurophet’s complete valuation and funding history, request access »

Neurophet Patents

  • 82

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 53

    Granted

  • 26

    Pending

  • 000

    Expiring in next 12 mo

Neurophet Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4358094-A1 Device and method for redesigning treatment prescription according to evaluation of therapeutic effectiveness Pending 31-Aug-2022 0000000000
US-20240071589-A1 System and method for redesigning treatment prescriptions according to evaluation of treatment effectiveness Pending 31-Aug-2022 000000000
EP-4231311-A1 Method and apparatus for providing information needed for dementia diagnosis Pending 22-Feb-2022 000000000 0
US-20230263457-A1 Method and apparatus for providing information needed for dementia diagnosis Active 22-Feb-2022 0000000000
EP-4230144-A1 Apparatus and method for providing dementia diagnosis assistance information Pending 22-Feb-2022 A61B6/037
To view Neurophet’s complete patent history, request access »

Neurophet Executive Team (8)

Name Title Board Seat
Junkil Been Co-Founder & Chief Executive Officer
ChangIl Kim Chief Product Officer
YoungJoon Moon Chief Business Officer
KwangMin Lee Chief Financial Officer
Donghyeon Kim Ph.D Co-Founder, Chief Technology Officer & CRO
You’re viewing 5 of 8 executive team members. Get the full list »

Neurophet Board Members (1)

Name Representing Role Since
Seungjae Baek Self Board Member 000 0000
To view Neurophet’s complete board members history, request access »

Neurophet Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurophet Investors (30)

Investor Name Investor Type Holding Investor Since Participating Rounds
Samjin Pharmaceutical Company Corporation Minority 000 0000 000000 0
DB Financial Investment Asset Manager Minority 000 0000 000000 0
KB Securities Investment Bank Minority 000 0000 000000 0
Mirae Asset Securities Investment Bank Minority 000 0000 000000 0
Seoile & M Corporation Minority 000 0000 000000 0
You’re viewing 5 of 30 investors. Get the full list »

Ready to get started?

Request a free trial

Neurophet FAQs

  • When was Neurophet founded?

    Neurophet was founded in 2015.

  • Who is the founder of Neurophet?

    Junkil Been and Donghyeon Kim Ph.D are the founders of Neurophet.

  • Who is the CEO of Neurophet?

    Junkil Been and ChangIl Kim are the CEOs of Neurophet.

  • Where is Neurophet headquartered?

    Neurophet is headquartered in Seoul, South Korea.

  • What is the size of Neurophet?

    Neurophet has 118 total employees.

  • What industry is Neurophet in?

    Neurophet’s primary industry is Decision/Risk Analysis.

  • Is Neurophet a private or public company?

    Neurophet is a Private company.

  • What is Neurophet’s current revenue?

    The current revenue for Neurophet is 00000.

  • How much funding has Neurophet raised over time?

    Neurophet has raised $38.7M.

  • Who are Neurophet’s investors?

    Samjin Pharmaceutical Company, DB Financial Investment, KB Securities, Mirae Asset Securities, and Seoile & M are 5 of 30 investors who have invested in Neurophet.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »